WE ARE DEVELOPING
NEUROMODULATION
THERAPIES FOR PATIENTS
SUFFERING FROM OBSTRUCTIVE SLEEP APNEA
WE ARE DEVELOPING
NEUROMODULATION
THERAPIES FOR PATIENTS
SUFFERING FROM OBSTRUCTIVE SLEEP APNEA
ABOUT AVIVOMED
Avivomed is a Minneapolis-based medical device company pioneering the development of next-generation minimally invasive neuromodulation therapies aimed at improving quality of life for patients suffering from obstructive sleep apnea.
Building on the NuXcel innovation ecosystem, Avivomed is backed by a world-class syndicate of investors including F-Prime,
Hatteras Venture Partners, Norwest, Treo Ventures, and others.
About Obstructive Sleep Apnea
Sleep apnea affects over 1B people worldwide1.
Mild-to-moderate obstructive sleep apnea (OSA) is marked by repeated airway collapse during sleep which triggers the brain to wake up and take a breath.
The resulting poor sleep has been linked to hypertension, cardiovascular disease, diabetes, and increased mortality2.
CPAP is the most common treatment but up to 50% of patients cannot tolerate it and search for alternative therapies such as neuromodulation3
Meet The Leadership Team
Paul Mazanec
Chief Executive Officer
Founders
Lynn Elliott
Co-Founder
Mudit Jain, PhD, MBA
Co-Founder
Board of Directors
Casper de Clercq, MS, MBA
Mudit Jain, PhD, MBA
Tracy Pappas
Ketan Patel, MD, MBA
Doug Reed, MD, MBA
Careers
Please contact info@avivomed.com
Send a note to Steve
Contact Us
LOCATION
Avivomed, Inc.
2896 Centre Pointe Drive
Roseville MN 55113
1. Benjafield, A. V., et al. (2019). "Global prevalence of obstructive sleep apnea: A systematic review and
meta-analysis." The Lancet Respiratory Medicine, 7(3), 237–247.
2. Peppard, P. E., et al. (2013). "Longitudinal Study of Moderate to Severe Obstructive Sleep Apnea and
Hypertension." JAMA Otolar695yngology–Head & Neck Surgery, 139(11), 1155–1162.
3. Weaver, T. E., et al. (2012). "Adherence to Continuous Positive Airway Pressure Treatment in Patients with
Obstructive Sleep Apnea." Sleep, 35(5), 689–.